BNP Paribas Financial Markets
RPRX

BNP Paribas Financial Markets’s Repros Therapeutics Inc. RPRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-573
Closed -$4.92K – 3780
2015
Q1 		$4.92K Buy
+573
New +$5.13K ﹤0.01% 3168
2014
Q4 		– Sell
-1,375
Closed -$13.6K – 4240
2014
Q3 		$13.6K Buy
1,375
+1,348
+4,993% +$20K ﹤0.01% 3420
2014
Q2 		$467 Buy
+27
New +$440 ﹤0.01% 3604
2014
Q1 		– Sell
-297
Closed -$5.43K – 4317
2013
Q4 		$5.43K Buy
+297
New +$5.61K ﹤0.01% 3046

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

BNP Paribas Financial Markets's RPRX Position: Q2 2015 in Review

BNP Paribas Financial Markets sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 573 shares — an estimated $4.92K sold.

BNP Paribas Financial Markets first reported a position in RPRX in Q4 2013 and held it in 4 quarters. The position peaked at $13.6K in Q3 2014. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

  • BNP Paribas Financial Markets reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 573 Repros Therapeutics Inc. shares in Q2 2015, an estimated $4.92K.
  • BNP Paribas Financial Markets first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 4 quarters.
  • BNP Paribas Financial Markets's Repros Therapeutics Inc. position peaked at $13.6K in Q3 2014.
  • 64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2015, filed 14 Aug 2015.